• Joan H Dunlop.
• Pediatrics, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA jdunlop7@jhmi.edu.
• J. Investig. Med. 2020 Aug 1; 68 (6): 1152-1155.

AbstractThe US Food and Drug Administration's approval of a peanut oral immunotherapy product in January 2020 is a landmark development in the field of food allergy therapy. While food allergy prevalence has been increasing, this product is the first approved therapy for food allergy. Oral immunotherapy has many similarities to subcutaneous immunotherapy and drug desensitization protocols, but does not lead to sustained unresponsiveness. The studies leading to approval of the Palforzia product demonstrated increase in the amount of peanut protein able to be consumed, with 67% of subjects randomized to the treatment arm able to consume 600 mg of peanut protein in double-blind placebo-controlled food challenge at study exit. However, side effects are an important consideration, and dropout rates in studies of Palforzia ranged from 11% to 21%. Postmarketing surveillance of this product will be critical in assessing its long-term risks and benefits.© American Federation for Medical Research 2020. No commercial re-use. See rights and permissions. Published by BMJ.

14 keywords...

hide…